MAIA Biotechnology, Inc. (MAIA) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$8.32M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$6.95M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$9.36M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$5.17M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$8.32M | (m) | (m) | (m) | (m) | -$6.75M* | (m) | $179.11K* | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$6.95M | (m) | (m) | (m) | (m) | -$5.31M | (m) | $43.65K | (m) | $339.00 |
| 2025-09-30 | Reported | (m) | -$9.36M | (m) | (m) | (m) | (m) | -$3.49M* | (m) | (m) | (m) | $0.00* |
| 2025-06-30 | Reported | (m) | -$5.17M | (m) | (m) | (m) | (m) | -$4.14M* | (m) | -$3.17M* | (m) | $0.00* |
| 2025-03-31 | Reported | (m) | -$5.43M | (m) | (m) | (m) | (m) | -$4.20M | (m) | $3.20M | (m) | $0.00 |
| 2024-09-30 | Reported | (m) | -$4.19M | (m) | (m) | (m) | (m) | -$3.52M* | (m) | $2.67M | (m) | $0.00* |
| 2024-06-30 | Reported | (m) | -$3.82M | (m) | (m) | (m) | (m) | -$4.68M* | (m) | $2.05M | (m) | $0.00* |
| 2024-03-31 | Reported | (m) | -$3.95M | (m) | (m) | (m) | (m) | -$3.59M | (m) | $2.32M | (m) | $0.00 |
| 2023-09-30 | Reported | (m) | -$4.96M | (m) | (m) | (m) | (m) | -$3.16M* | (m) | $2.60M | (m) | $0.00* |
| 2023-06-30 | Reported | (m) | -$4.66M | (m) | (m) | (m) | (m) | -$2.56M* | (m) | $2.60M | (m) | $0.00* |
| 2023-03-31 | Reported | (m) | -$4.18M | (m) | (m) | (m) | (m) | -$3.36M | (m) | $2.20M | (m) | $0.00 |
| 2022-09-30 | Reported | (m) | -$5.10M | (m) | (m) | (m) | (m) | -$4.32M* | (m) | $2.34M | (m) | $0.00* |
| 2022-06-30 | Reported | (m) | -$3.44M | (m) | (m) | (m) | (m) | -$2.02M* | (m) | $2.12M | (m) | $0.00* |
| 2022-03-31 | Reported | (m) | -$3.44M | (m) | (m) | (m) | (m) | -$2.81M | (m) | $2.08M | (m) | $0.00 |
| 2021-09-30 | Reported | (m) | -$2.23M | (m) | (m) | (m) | (m) | -$1.31M* | (m) | $1.08M | (m) | $0.00* |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$24.27M | (m) | (m) | (m) | (m) | -$18.84M | (m) | $453.75K | (m) | $2.00K |
| 2024-12-31 | Reported | (m) | -$16.96M | (m) | (m) | (m) | (m) | -$15.70M | (m) | $10.01M | (m) | $2.00K |
| 2023-12-31 | Reported | (m) | -$20.18M | (m) | (m) | (m) | (m) | -$13.07M | (m) | $11.11M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$16.18M | (m) | (m) | (m) | (m) | -$12.10M | (m) | $8.93M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$7.79M | (m) | (m) | (m) | (m) | -$4.12M | (m) | $3.50M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |